Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
about
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitroThe role of drug transporters in the kidney: lessons from tenofovirExpression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral DrugsDrug interactions and antiretroviral drug monitoring.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patientsImpact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.The role of human carboxylesterases in drug metabolism: have we overlooked their importance?Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Renal function with use of a tenofovir-containing initial antiretroviral regimenInteractions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells.Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.Antiviral drug disposition and natural health products: risk of therapeutic alteration and resistance.Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.The role of tenofovir alafenamide in future HIV management.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.Renal effects of novel antiretroviral drugs.A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios.Renal Drug Transporters and Drug Interactions.Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions.Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans.Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort StudyDevelopment of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate.Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Population pharmacokinetics of tenofovir in AIDS patients.Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.
P2860
Q24633870-C6BFA9F6-43B2-4BC3-887B-99EC4B62FCBAQ26866489-C548648F-B8D9-4351-ABF4-CF7E8135FC96Q28548592-7A7D2679-A75D-4E0D-ABED-8EE4067CDF66Q34021173-01680170-9E2B-45B1-943B-BCDBF06FEAB6Q34478840-AC243FA1-1DB5-48D6-A9F3-C9601248BB32Q35191539-C26BAFEE-ABF4-47D1-97CC-509664B7A359Q35607723-1ED19C23-FFCD-4F7F-A44A-BA2EA570FA68Q35812127-5012DB13-42B5-40F1-8C53-5024D0AF422EQ36066647-5EB89324-1F5E-4850-B10A-23E23D35DB25Q36219963-D2B035BB-FA9A-40FB-97FB-9D731378A11AQ36492436-2FDA9341-5A91-4FC0-B24B-6D9551EAFFD6Q36553973-2D820606-C22C-4633-9348-1E6F7E3454E5Q37113947-AE473126-DFA4-4A92-8CB5-2618D2E416B3Q37190767-D2F0B089-74BD-4D53-91A3-72ECA83B81B0Q37215065-0FE94430-F5AD-44D8-8AC2-98D20B904238Q37394900-3A5B9A7C-5096-4D29-B185-6AEEEAAB9789Q37421891-8DAD5DD7-FF2A-4280-9B9A-1A34EE3EF6EFQ37481442-3CBB8D60-8304-4FDF-9E19-7EF4048AAC18Q38040137-CA51FB7F-760D-4914-8557-CEC84F65556DQ38222708-EED2EBC3-572C-4EFC-95E5-5D358831DDCBQ38764695-3EBA9BC9-E725-4908-9CF7-30B5CA1821CFQ38798813-E0766CD6-D2E6-4193-9A9E-9A24254C32F7Q38833637-B8FDC847-C489-4F49-9CA3-2D6625D0AD2DQ38837077-B5636671-2C6A-4433-865E-D83C56063D44Q38956287-BE147449-DE84-4921-8C57-33D51878F3D9Q39140289-2FA428B6-3D72-4476-BAD1-89837167874EQ39229674-4C403A51-7EE1-4AE6-B6D6-042C8E9C561AQ39801648-D4E0808E-36CC-4377-A7E7-88F9EB987917Q40119350-5011D83D-CD4E-4848-B026-57FB501E3749Q40148984-83EB0A5C-E275-493B-90E2-051CB472FFECQ40707587-A4E76198-B4EF-40F2-866D-BE2F631CF134Q42037463-D558443D-0286-474A-9219-16E7AFFDB12EQ42679799-6DE23DB0-BE14-45E6-A294-EEDA450EA11EQ43689055-877981FB-242C-4BE6-9837-C990D0834EDCQ44737065-C3C57E0F-50A5-4B04-BC5E-BBD63C7B99D3Q45349377-B0842373-4C0C-4388-9FD5-6AFC7D8BB52DQ46106006-3F41A635-26E1-4126-BEC5-0404E9CFFA40Q46323872-DD223C14-DB21-4C2E-B42A-D2B1C421855DQ46492450-1328EF47-DB4A-4AAD-A242-B367C02D138CQ47633560-75000D6F-4A9B-45D9-9E59-F4F65DCCB43D
P2860
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Effects of human immunodeficie ...... disoproxil fumarate in vitro.
@en
type
label
Effects of human immunodeficie ...... disoproxil fumarate in vitro.
@en
prefLabel
Effects of human immunodeficie ...... disoproxil fumarate in vitro.
@en
P2093
P2860
P356
P1476
Effects of human immunodeficie ...... r disoproxil fumarate in vitro
@en
P2093
Darius Babusis
Gerald R Rhodes
Ismael J Hidalgo
Kelly L Robinson
Robert Strab
Siddhartha Bhoopathy
Truc K Phan
P2860
P304
P356
10.1128/AAC.00671-07
P407
P577
2007-07-30T00:00:00Z